Emergent BioSolutions faces margin pressure, lowered FY26 guidance, and weak profitability despite cost cuts. Learn more about EBS stock here.
Detailed price information for Emergent Biosolutions (EBS-N) from The Globe and Mail including charting and trades.
Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Emergent BioSolutions (EBS) outlook: MCM strength vs. NARCAN impairment and naloxone decline. Read here for a detailed investment analysis.
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans
Emergent BioSolutions (EBS) downgraded to Hold as Narcan sales slip, competition rises and debt persists; review risks, cash flow signals and act now.
Emergent BioSolutions (EBS) said Thursday that it has completed the repurchase of $75 million aggreg
Repurchase reduces unsecured note balance to approximately $364.7 millionManagement to discuss this key milestone and broader transformation progress at upcoming investor conferences GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Senior Unsecured Notes”), following authorization granted by its Board of Dir
This is the newest page. Registered accounts read further back.